Alex Cammack
@alexcammack.bsky.social
Postdoctoral fellow at UCL and the UK DRI
Reposted by Alex Cammack
Our new review on the challenges of modelling TDP-43 pathology in mice is just out:
rdcu.be/ejZ5a
As usual, together with Lizzy Fisher. Thanks to Jose Brito and @lucastaoro.bsky.social from the lab for putting the data together for the comprehensive tables.
rdcu.be/ejZ5a
As usual, together with Lizzy Fisher. Thanks to Jose Brito and @lucastaoro.bsky.social from the lab for putting the data together for the comprehensive tables.
Challenges of modelling TDP-43 pathology in mice
rdcu.be
April 30, 2025 at 4:20 PM
Our new review on the challenges of modelling TDP-43 pathology in mice is just out:
rdcu.be/ejZ5a
As usual, together with Lizzy Fisher. Thanks to Jose Brito and @lucastaoro.bsky.social from the lab for putting the data together for the comprehensive tables.
rdcu.be/ejZ5a
As usual, together with Lizzy Fisher. Thanks to Jose Brito and @lucastaoro.bsky.social from the lab for putting the data together for the comprehensive tables.
Reposted by Alex Cammack
A first description of the C9 repeat iNDI lines is now on bioRxiv, a collaboration from genome engineering through cell biology to facilitate ALS/FTD research @michael-e-ward.bsky.social @jacksonlab.bsky.social @cziscience.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Generation of C9orf72 repeat knock-in iPSC lines for modelling ALS and FTD
Induced pluripotent stem cell (iPSC) models are powerful tools for neurodegenerative disease modelling, as they allow mechanistic studies in a human genetic environment and they can be differentiated ...
www.biorxiv.org
February 11, 2025 at 1:46 PM
A first description of the C9 repeat iNDI lines is now on bioRxiv, a collaboration from genome engineering through cell biology to facilitate ALS/FTD research @michael-e-ward.bsky.social @jacksonlab.bsky.social @cziscience.bsky.social
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Reposted by Alex Cammack
First post here! Our latest paper showing CRISPR-CasRx can target both sense and antisense C9orf72 repeats is just out! rdcu.be/d5ADQ co-led by @alexcammack.bsky.social @ukdri.bsky.social @uclqsion.bsky.social
Dual-targeting CRISPR-CasRx reduces C9orf72 ALS/FTD sense and antisense repeat RNAs in vitro and in vivo
Nature Communications - CRISPR-CasRx effectively reduces ALS- and FTD-causing C9orf72 sense and antisense repeat derived RNAs and proteins in cell lines, patient iPSC-neurons and two independent...
rdcu.be
January 8, 2025 at 11:41 AM
First post here! Our latest paper showing CRISPR-CasRx can target both sense and antisense C9orf72 repeats is just out! rdcu.be/d5ADQ co-led by @alexcammack.bsky.social @ukdri.bsky.social @uclqsion.bsky.social